Additionally, it highlights the role of these proteins as biomarkers for diagnosis and prognosis in ovarian cancer, and delves into novel therapeutic strategies currently under development that target GLUT isoforms. This evidence concerns the gene SLC2A1 and ovarian carcinoma.